Federated Hermes Inc. Acquires 2,251,497 Shares of Moderna, Inc. $MRNA

Federated Hermes Inc. increased its stake in Moderna, Inc. (NASDAQ:MRNA) by 364.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,869,271 shares of the company’s stock after purchasing an additional 2,251,497 shares during the quarter. Federated Hermes Inc. owned approximately 0.74% of Moderna worth $79,163,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Cetera Investment Advisers increased its position in Moderna by 20.7% in the first quarter. Cetera Investment Advisers now owns 49,215 shares of the company’s stock worth $1,395,000 after buying an additional 8,432 shares in the last quarter. Natixis Advisors LLC increased its holdings in Moderna by 70.7% in the 1st quarter. Natixis Advisors LLC now owns 17,761 shares of the company’s stock worth $504,000 after acquiring an additional 7,356 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Moderna by 39.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 37,887 shares of the company’s stock worth $1,074,000 after acquiring an additional 10,761 shares during the period. ASR Vermogensbeheer N.V. purchased a new position in Moderna during the first quarter valued at approximately $614,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Moderna by 12.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock valued at $74,557,000 after purchasing an additional 285,662 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Trading Up 8.7%

Shares of MRNA stock opened at $27.70 on Monday. The stock has a market capitalization of $10.82 billion, a price-to-earnings ratio of -3.43 and a beta of 1.11. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $48.92. The stock’s 50-day moving average price is $25.86 and its 200-day moving average price is $26.98.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($2.15) by $1.64. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $893.29 million. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The firm’s revenue was down 45.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.03 earnings per share. As a group, research analysts predict that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MRNA. Wolfe Research reissued an “underperform” rating and issued a $17.00 price objective on shares of Moderna in a research note on Thursday, November 20th. Barclays decreased their price target on Moderna from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Friday, November 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Monday, October 20th. Bank of America decreased their target price on Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a research note on Monday, November 10th. Finally, UBS Group reissued a “buy” rating on shares of Moderna in a report on Friday, November 21st. Two analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $29.46.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.